|
GB201801562D0
|
|
Pharmaceutical compounds
|
|
WO2017216559A1
|
|
Predicting responsiveness to therapy in prostate cancer
|
|
US2019127805A1
|
|
Gene signatures for cancer detection and treatment
|
|
GB201700776D0
|
|
Predicting responsiveness to therapy in prostate cancer
|
|
GB201621384D0
|
|
Gene signatures for cancer detection and treatment
|
|
GB201621398D0
|
|
Treatment of emt-associated disease
|
|
GB201610362D0
|
|
Predicting responsiveness to therapy in prostate cancer
|
|
GB201609944D0
|
|
Gene signatures for cancer detection and treatment
|
|
GB201604398D0
|
|
Gene signatures for cancer detection and treatment
|
|
GB201512869D0
|
|
Gene signature for minute therapies
|
|
GB201510684D0
|
|
Gene signatures predictive of metastatic disease
|
|
GB201409476D0
|
|
Molecular subtype for use in prognosis
|
|
GB201409479D0
|
|
Molecular diagnostic test for cancer
|
|
GB201409478D0
|
|
Pro-angiogenic signature
|
|
GB201322034D0
|
|
Prostate cancer classification
|
|
US2016002732A1
|
|
Molecular diagnostic test for cancer
|
|
GB201316027D0
|
|
Molecular diagnostic test for oesophageal cancer
|
|
GB201316024D0
|
|
Molecular diagnostic test for lung cancer
|
|
WO2012167278A1
|
|
Molecular diagnostic test for cancer
|
|
AU2012202562A1
|
|
Transcriptome microarray technology and methods of using the same
|
